Mannitol Use in Emergency Department
For acute reduction of elevated intracranial pressure in the emergency department, administer mannitol 20% at 0.25-1 g/kg IV over 15-30 minutes, with larger doses (0.5-1 g/kg over 15 minutes) appropriate for acute intracranial hypertensive crisis. 1, 2
Dosing by Clinical Indication
Increased Intracranial Pressure
- Standard dose: 0.25-1 g/kg IV over 20-30 minutes 1
- Acute crisis: 0.5-1 g/kg over 15 minutes for impending herniation 1
- Pediatric: 0.25-1.5 g/kg, though evidence base is limited 3
- Small/debilitated patients: 500 mg/kg 2
The 2026 AHA/ASA stroke guidelines confirm mannitol's role as a bridge to surgical intervention in patients with large cerebral or cerebellar infarctions showing neurological decline from brain swelling 4. The 2018 French TBI guidelines recommend 250 mOsm doses (approximately 0.5-1 g/kg of 20% mannitol) over 15-20 minutes for threatened intracranial hypertension or herniation signs 5.
Elevated Intraocular Pressure
- Adult dose: 0.25-2 g/kg as 15-25% solution over 30-60 minutes 2
- Pediatric: 1-2 g/kg or 30-60 g/m² over 30-60 minutes 2
Research confirms mannitol effectively reduces IOP in both vitrectomized and non-vitrectomized eyes, with significant reductions observed within 30-60 minutes 6, 7.
Administration Protocol
Preparation and Delivery
- Concentration: Use 20% or 25% solution 5, 2
- Filter requirement: Administer through a filter; do not use solutions containing crystals 1, 2
- Infusion time: 15-30 minutes depending on urgency 1, 5
- Do NOT mix with whole blood for transfusion 2
Expected Response Timeline
- Peak effect: 40-44 minutes after infusion start 8, 9
- Duration: 2-4 hours typically 5
- ICP reduction: Expect 10% or more reduction with doses ≥1 g/kg 8
The 2009 systematic review confirms mannitol effectively reduces ICP (Grade A evidence), though it does not improve neurological outcomes or survival in raised ICP states 10.
Critical Monitoring Parameters
Before Administration - Contraindications
- Absolute contraindications 2:
- Well-established anuria from severe renal disease
- Severe pulmonary congestion or frank pulmonary edema
- Active intracranial bleeding (except during craniotomy)
- Severe dehydration
- Progressive heart failure after mannitol initiation
- Known hypersensitivity to mannitol
During and After Administration
- Serum osmolality: Monitor closely; avoid exceeding 320 mOsm/L 5, 8
- Electrolytes: Check sodium, potassium, chloride regularly 5
- Fluid balance: Place urinary catheter before administration 1
- Volume status: Mannitol causes osmotic diuresis requiring fluid replacement 5
- Cardiovascular status: Monitor for hypotension, tachycardia, pulmonary congestion 2
Important Clinical Caveats
Hypertonic Saline as Alternative
The 2018 French guidelines state that at equiosmotic doses (250 mOsm), mannitol and hypertonic saline have comparable efficacy for treating intracranial hypertension 5. However, some evidence suggests hypertonic saline may be more effective: a 2005 RCT showed equimolar HSD (7.5% saline/6% dextran) produced greater and longer-lasting ICP reduction than 20% mannitol 11. The 2022 ICH guidelines note that hypertonic saline may be more effective than mannitol in equiosmolar doses 12.
Key difference: Mannitol requires volume replacement due to diuresis, while hypertonic saline risks hypernatremia and hyperchloremia 5.
Special Populations
- Traumatic brain injury in children: Mannitol may worsen intracranial hypertension in those developing generalized cerebral hyperemia within 24-48 hours post-injury 2
- Neurosurgical patients: May increase cerebral blood flow and postoperative bleeding risk 2
- Hypotensive patients: Use with extreme caution; mannitol is "often used but has limited pediatric evidence base, beware in hypotension" 3
Adjunctive Measures
Mannitol should be used alongside other ICP control measures 1:
- Head-of-bed elevation
- Sedation/analgesia
- Cerebrospinal fluid drainage (if EVD present)
- Avoid prolonged hyperventilation (worsens outcomes) 5
- Consider barbiturates or neuromuscular blockade in refractory cases
Repeat Dosing Considerations
- Unpredictable duration: Return to baseline ICP varies with initial ICP and fluid replacement volume 8
- Continuous infusion: Can be used for 6-100 hours if needed to maintain ICP <25 mmHg, requiring 2-20 mg/kg total dose 8
- Rebound phenomenon: Risk of cerebral edema with frequent administration 13
When to Discontinue
Stop mannitol immediately if 2:
- Renal function deteriorates
- Cardiac or pulmonary status worsens
- CNS toxicity develops
- Progressive heart failure or pulmonary congestion occurs